National and Kapodistrian University of Athens
Γενετική προδιάθεση μεταβολικού συνδρόμου σε υγιείς μετεμμηνοπαυσιακές γυναίκες και αλληλεπίδραση με την ορμονική θεραπεία
Abstract
dc:descriptionIntroduction: Postmenopausal women have an increased prevalence of the metabolic syndrome and this is attributed to a complex interaction between environmental and genetic factors. The aim of the present study was to investigate the impact of Methylenetetrahydrofolate reductase (ΜΤΗFR) C677T polymorphism and Plasminogen activator inhibitor - 1 polymorphism (PAI-1) 4G/5G on the metabolic syndrome, its separate components and other metabolic indices in postmenopausal women under hormone therapy.Methods: The study population consisted of 160 postmenopausal women and 145 of them received per os 1mg estradiol/2mg drospirenone (N=70) or transdermal 50 mcg estradiol/250 mg norethisterone (N=17) or per os 2.5 mg tibolone (N=27) or 60 mg raloxifene (N=31). The control group consisted of 15 postmenopausal women who did not receive any treatment regarding menopause. Multiplex polymerase chain reaction (PCR) was used to assess the presence of the two polymorphisms. One year later the participants were re-examined regarding the presence of the metabolic syndrome, its components and changes in other metabolic assays in the several subgroups formed based on the administered hormone therapy and the presence of the examined polymorphisms.Results: In the subgroup of women who received per os estradiol/drospirenone the TT genotype correlated with an increase in total and LDL cholesterol compared to the other two genotypes in which the same indices were decreased under the same treatment (P=0.032, P=0.002 και P=0.011 respectively). In the same subgroup the 4G/4G genotype was associated with increased systolic blood pressure (P=0.049), lipoprotein a (P=0.024) and insulin (P=0.049) levels compared to the 4G/5G and 5G/5G genotypes. In the transdermal hormone therapy subgroup the presence of the 4G allele led to decreased triglycerides (P=0.025) and increased HDL cholesterol (P=0.010) and apolipoprotein B levels (P=0.004). In the tibolone subgroup postmenopausal women homozygous for the 4G allele emerged a more intense decrease of HDL and apolipoprotein levels (P=0.014, P=0.014 respectively), while they experienced a smaller increase of their diastolic pressure (P=0.027) compared to the other two genotypes. Finally, in the raloxifene subgroup the T allele associated with a greater increase of apolipoprotein B and insulin levels (P=0.044, P=0.028 respectively). In the same subgroup the 4G allele correlated with a relatively smaller increase of glycosylated haemoglobin, a decrease of diastolic blood pressure (P=0.046, P=0.049 respectively) and an increase of the waist to hip ratio compared to the normal genotype ( P=0.015).Conclusions: The MTHFR C677T and PAI-1 4G/5G polymorphisms modified the impact of postmenopausal hormone therapy on the metabolic syndrome components and other metabolic indices. The present study contributes to the elucidation of the genetic component of the metabolic syndrome in postmenopausal women.
Degree
thesis:*- Grantor dc:publisher
- National and Kapodistrian University of Athens
- Year dc:date
- 2014
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Papadimitriou, Dimitra
- Παπαδημητρίου, Δήμητρα
Subjects
dc:subject × 18- Μεταβολικό σύνδρομο
- Εμμηνόπαυση
- Πρόληψη καρδιαγγειακών νοσημάτων
- Πολυμορφισμός της μεθυλενετετραϋδροφυλλικής ρεδουκτάσης MTHFR C677T
- Ορμονική θεραπεία
- Πολυμορφισμός του αναστολέα του ενεργοποιητή του πλασμινογόνου PAI-1 4G/5G
- Metabolic syndrome
- Menopause
- Prevention of cardiovascular diseases
- Methylenetrahydrofolate polymorphism MTHFR C677T
- Plasminogen activator inhibitor polymorphism PAI-1 4G/5G
- Hormone therapy
- Ιατρική και Επιστήμες Υγείας
- Βασική Ιατρική
- Κλινική Ιατρική
- Medical and Health Sciences
- Basic Medicine
- Clinical Medicine
Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/42150